HomeNewsBusinessMarketsSEBI relaxes preferential allotment norms; 4 ways in which it will help D-Street

SEBI relaxes preferential allotment norms; 4 ways in which it will help D-Street

The move will not only allow promoters to increase their holdings substantially, but will also make it easier for companies to raise funds from promoters

June 18, 2020 / 08:55 IST
Story continues below Advertisement

Capital market regulator, Securities and Exchange Board of India (SEBI) on June 17 relaxed the preferential allotment norms till March 2021.

SEBI has allowed promoters to increase their stake in the company by up to 10 percent through a preferential allotment, against the limit of 5 percent earlier.

Story continues below Advertisement

The move comes at a time when a lot of companies are in need of funds to start operations following the countrywide lockdown. It can help the companies to raise funds faster via promoters.

"With regard to the notification issued by SEBI for amending provision of SEBI (SAST) Regulations, promoters of the listed company were allowed to acquire shares up to 5% in any Financial year without making a public announcement of an open offer but with this amendment, promoters are allowed acquire shares up to 10% in FY21 by way of acquiring shares of their company through preferential allotment, which will be issued as per provision of SEBI (ICDR) Regulation," Shalibhadra Shah, CFO, MOFSL told Moneycontrol.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show